[关键词]
[摘要]
目的 研究桂枝茯苓胶囊联合米非司酮治疗子宫肌瘤的疗效及对患者血清孕激素受体(PR)、雌激素受体(ER)、血管内皮生长因子(VEGF)的影响。方法 选取2014年1月-2017年6月西安市北方医院妇产科收治的子宫肌瘤患者75例,随机分为对照组、观察组,各38、37例。对照组于月经的第3天口服米非司酮片12.5 mg,每天1次,于每晚睡前口服;观察组在对照组基础上于月经的第1天口服桂枝茯苓胶囊3粒,每天3次,疗程3个月。比较两组的临床治疗效果,比较两组治疗前后的子宫肌瘤体积、月经量以及子宫体积,以及血清ER、PR、VEGF水平变化。结果 观察组的有效率为94.59%(35/37),明显高于对照组的71.05%(27/38),差异有统计学意义(P<0.05)。两组治疗3个月后的子宫肌瘤体积、月经量以及子宫体积均明显降低,同组治疗前后比较差异有统计学意义(P<0.05),且观察组以上指标明显低于对照组,差异有统计学意义(P<0.05)。两组治疗3个月后的血清ER、PR、VEGF水平均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组以上指标明显低于对照组,差异有统计学意义(P<0.05)。所有患者均未出现低血压、体质量显著增加以及色素沉着等不良反应。结论 桂枝茯苓胶囊联合米非司酮对子宫肌瘤患者具有较为确切的治疗效果,不仅可以有效缩小子宫肌瘤体积以及子宫体积,还可以降低血清ER、PR、VEGF水平。
[Key word]
[Abstract]
Objective To investigate the clinical effect of Guizhi Fuling Pill on uterine myoma and its effect on serum ER, PR and VEGF. Methods Selected 75 cases of patients with uterine myoma who were treated in our hospital from January 2014 to December 2016, divided into two groups randomly. The control group was treated with Mifepristone Tablets 12.5 mg 1 times a day on the third day of menstruation. The observation group was treated with Guizhi Fuling Pill 3 times per day on the first day of menstruation, 3 times a day, comparing the clinical effect of two groups. Results After treatment, the effective rate of the observation group (94.59%) was significantly higher than that of the control group (71.05%) (P<0.05). The volume of uterine myoma, the amount of menstruation and the volume of uterus decreased significantly after 3 months of treatment (P<0.05), and the observation group was more obvious (P<0.05). The levels of serum ER, PR and VEGF in the two groups were significantly decreased after 3 months of treatment (P<0.05), and the observation group was more obvious (P<0.05). All patients had no adverse reactions such as hypotension, significant increase in weight, and pigmentation. Conclusions Guizhi Fuling Pill has a definite therapeutic effect for patients with uterine fibroids. It can not only effectively reduce the volume of uterine fibroids and uterine volume, but also reduce serum ER, PR and VEGF levels.
[中图分类号]
[基金项目]